Cerliponase alfa
Customize your policy alerts
Sign up for healthspring Policy RX501.092 alerts
Get alerted when Policy RX501.092 changes without checking for updates manually.
Monitor payer policy activity
This policy governs HealthSpring coverage and authorization considerations for cerliponase alfa. Coverage is subject to evidence of effectiveness, authoritative drug-therapy recommendations, applicable state requirements, and the member's benefit contract.
A new medical document establishes cerliponase alfa as potentially medically necessary for pediatric patients with neuronal ceroid lipofuscinosis type 2 and unproven for all other non-FDA-approved indications.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.